Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Jupiter Medical Center — Jupiter, Florida
- Sarasota Memorial Hospital-Venice — N. Venice, Florida
- AdventHealth Orlando — Orlando, Florida
- Florida Cancer Specialists - Sarasota Downtown — Sarasota, Florida
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Advent Health — Orlando, Florida
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in Florida: - Research Site — Jupiter, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Miami Beach, Florida
- Research Site — Orlando, Florida
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in Florida: - Research Site — Fort Myers, Florida
- Research Site — Miami Beach, Florida
- Research Site — Orlando, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Tampa, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicate…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06952504
Sites in Florida: - Florida Cancer Specialists - South ( Site 7003) — Fort Myers, Florida
- UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026) — Gainesville, Florida
- Mount Sinai Cancer Center ( Site 6031) — Miami Beach, Florida
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) — Orlando, Florida
- Florida Cancer Specialists ( Site 7002) — St. Petersburg, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endomet…
Sponsor: Genmab
NCT ID: NCT07166094
Sites in Florida: - SMH - Sarasota - Main Campus — Sarasota, Florida
Phase 3 Recruiting Industry
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how…
Sponsor: BioNTech SE
NCT ID: NCT06340568
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
Phase 3 Recruiting Industry
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Sponsor: Daiichi Sankyo
NCT ID: NCT07022483
Sites in Florida: - Mount Sinai Medical Center — Miami Beach, Florida
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Broward Health Medical Center — Fort Lauderdale, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 2 Recruiting Industry
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
NCT ID: NCT05548296
Sites in Florida: - Florida Gynecologic Oncology/Regional Cancer Center — Fort Myers, Florida
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
Phase 2 Recruiting Network
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05640999
Sites in Florida: - University of Miami School of Medicine — Miami, Florida
- Sarasota Memorial Hospital - Venice — N. Venice, Florida
- Florida Cancer Specialists - Sarasota Downtown — Sarasota, Florida
- First Physicians Group-Sarasota — Sarasota, Florida
- Sarasota Memorial Hospital — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida: - Florida Cancer Specialists — Fort Myers, Florida
- Mayo Clinic (Florida) — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Florida Cancer Specialists — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Florida: - USOR Florida Cancer Specialists South — Fort Myers, Florida
- USOR Florida Cancer Specialists North — St. Petersburg, Florida
- USOR Florida Cancer Specialists East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Florida: - Advanced Research LLC — Coral Springs, Florida
- The Oncology Institute of Hope and Innovation — Lakeland, Florida
- D&H Cancer Research Center LLC — Margate, Florida
- HCA Mercy Hospital — Miami, Florida
- BRCR Medical Center Inc. — Plantation, Florida
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida: - University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- Advent Health — Orlando, Florida
- Florida Cancer Specialists South — Port Charlotte, Florida
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Florida: - Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…
Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in Florida: - AdventHealth Orlando — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Florida: - University of Miami — Coral Gables, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Florida: - Florida Cancer Specialists — Lake Mary, Florida
Phase 1, Phase 2 Recruiting Academic/Other
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer.…
Sponsor: Alliance Foundation Trials, LLC.
NCT ID: NCT04486352
Sites in Florida: - Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida: - Florida Cancer Specialists — Sarasota, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in Florida: - Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Florida Cancer Specialists, North — St. Petersburg, Florida
- Florida Cancer Specialists, East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Florida: - AdventHealth Celebration — Celebration, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida